RDD Blog » CRO

R&D Directions Insider

Archive for the ‘ CRO ’ Category

Pediatric trial education in focus

Monday, November 14th, 2011

With new legislation and regulatory polices calling for more pediatric research as part of a drug-development program, the need for increased education around pediatric clinical trials is paramount, experts in this space stress. Unlike the case under earlier regulations, companies developing a drug intended for an adult market can no ...

Posted in CRO, Uncategorized, clinical trials | No Comments »

PPD to be acquired by private investment company

Tuesday, October 4th, 2011

Morningstarâ€™s Lauren Migliore believes that the contract research organization industry has turned a corner, citing a resurgence in new business activity and revenue growth during the past few quarters. She notes that â€œthe second quarter marked the first period since the beginning of the drug-development slowdown that the ...

Posted in CRO | No Comments »

‘Lower costs and better outcomes are mission critical’ for sponsors

Wednesday, July 27th, 2011

We reported last week that Wendel Barr, the former chief operating officer at contract research giant Covance and 11-year executive with the company, was named CEO of Synteract, a smaller privately held CRO based in San Diego. We caught up with Mr. Barr after his move across country (Covance headquarters are ...

Posted in CRO, Uncategorized | No Comments »

Covance exec takes head reins at smaller CRO

Monday, July 18th, 2011

Today, I was alerted to an interesting hire in the CRO arena, where executives jumping from one company to another is fairly common. This one, however â€“ the appointment this morning of Wendel Barr as the new CEO of San Diego-based Synteract Inc. â€“ is worth noting because of the ...

Posted in CRO, Uncategorized | 1 Comment »

Adding to the tally …

Thursday, July 14th, 2011

In case you missed it, two more acquisitions in the CRO space were completed this week. Today, InVentiv Health finalized its deal to buy PharmaNet Development Group (InVentiv added i3 in June). On Tuesday, INC Research sealed its $232 million acquisition of Kendle International Inc. These deals are just the latest ...

Posted in CRO, Uncategorized | No Comments »

Pfizer pacts are further proof of CRO shift

Wednesday, June 8th, 2011

Itâ€™s no secret Pfizer, perhaps more than any other big pharma, is looking to â€œgain efficienciesâ€ in R&D at every turn. Gaining efficiencies, of course, is just a fancy way of describing the need to cut costs, which it appears Pfizer, as it looks to divest many of its businesses, ...

Posted in CRO, Uncategorized, clinical trials | No Comments »

INC exec: Global scale-up key driver of Kendle deal

Friday, May 13th, 2011

We caught up with INC Researchâ€™s chief operating officer John Potthoff, Ph.D., by email for more on INCâ€™s big deal to acquire CRO rival Kendle, a move that could elevate the privately held company into a top five industry player. R&D Directions: How will the acquisition of Kendle position INC ...

Posted in CRO, Uncategorized, clinical trials | No Comments »

Omnicare CR acquired by Nautic Partners

Thursday, April 28th, 2011

Mid-sized contract research organization Omnicare Clinical Research has been acquired by Nautic Partners LLC, a private equity firm based in Providence, R.I. The deal marks the separation of Omnicare from former parent company, Omnicare Inc., a distributor of pharmaceutical care to the elderly, with $600 billion in annual revenue. The transaction ...

Posted in CRO | No Comments »

Quintiles backs innovative breast cancer trial

Thursday, April 14th, 2011

Today, Quintiles got into the "spy" game - the I-SPY 2 clinical trial, to be exact. The contract research organization has committed a total of $2.6 million over four years to support the trial, formally known as the "Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular ...

Posted in CRO, FDA, clinical trials, drug discovery | No Comments »

Behind the NICE Alzheimer’s reversal

Friday, November 5th, 2010

You may be wondering what convinced the National Institute for Health and Clinical Excellence, U.K.â€™s controversial drug-cost watchdog, to reverse its restrictions on four top Alzheimerâ€™s disease medicines last month, opening up potential access to hundreds of thousands of sufferers previously denied coverage. No, it doesnâ€™t appear the result of a ...

Posted in CRO, Uncategorized | No Comments »

©2012 UBM Canon